Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer

Nagata, T.; Fukuda, Kazunori; Tamai, Mizuki; Taniguchi, Akihiro; Kamiya, Hajime; Kambe, Kosuke; Kamada, Yosuke; Iwata, George; Yamaoka, Nobuki

doi:10.21873/anticanres.13248

Cited by 5 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the addition of oxaliplatin, in our study, severe toxicity rate was relative low (17%) and in any case equal to or better than previously published studies; both randomized studies, that tested oxaliplatin in the neoadjuvant setting (from 23% up to 40%) (14-17), and in a retrospective elderly series (from 12% up to 35%) (18)(19)(20). Even if oxaliplatin is probably responsible for improving toxicity incidence, it is well-known that oxaliplatin mainly causes neurotoxic adverse events due to cell death in neural ganglia of the dorsal spinal nerve root (21). We recorded 21 patients (21%) with peripheral neuropathy and 71% of these patients (n=15) showed complete recovery several months after oxaliplatin infusion.…”

Section: Discussionmentioning

confidence: 92%

Tolerability of Oxaliplatin-based Neoadjuvant Chemoradiotherapy in Elderly Locally Advanced Rectal Cancer Patients: A Case-control Study of a Real-life Experience

et al. 2019

View full text Add to dashboard Cite

Background/Aim: The aim of this study was to delineate clinical criteria to safely select elderly patients who can benefit from adding oxaliplatin to 5-fluoruracil-based neo-adjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) management. Patients and Methods: This is a single-institutional case-control study on LARC patients who received intensified neo-adjuvant CRT, between January 2007 and December 2014. Data concerning patient characteristics, treatment details and adverse events were reviewed and analyzed in two settings: young patients (<65 years) and elderly (≥65 years). A binary logistic model was applied to analyze the potential interaction between clinical variables and severe toxicity risk. Results: In total, 100 consecutive LARC patients were included. Mean age was 63.6 years and 55% (n=55) of the patients had adult comorbidity evaluation-27 (ACE-27) score ≥1. Most cancers (81%) were lymph node positive at diagnosis. Overall, ≥5 cycles of oxaliplatin were administered to 92 patients (92%). Only 17 patients (17%) reported grade ≥3 toxicity. The elderly group did not experience significantly higher severe toxicity than the young group. ACE-27 score ≥1 was the only variable independently associated with a higher severe toxicity. The 5-year overal survival (OS) rates were 64.1% and 89.2% in the elderly and young cohort, respectively. Conclusion: Elderly LARC patients can be safely treated with intensified neo-adjuvant CRT.

show abstract

Section: Discussionmentioning

confidence: 92%

Tolerability of Oxaliplatin-based Neoadjuvant Chemoradiotherapy in Elderly Locally Advanced Rectal Cancer Patients: A Case-control Study of a Real-life Experience

et al. 2019

View full text Add to dashboard Cite

show abstract

“…These acute symptoms are experienced by most of patients (90%) at some point of time during treatment [18,20,22], being usually reversible within hours or days and typically is triggered or exacerbated by cold [18,21,23,47] (Table 2). Similar to persistent OXAIPN, no factors beyond dose or infusion time seem related with the risk of developing acute OXAIPN [10,21,[23][24][25][26][27][28]. Acute neurotoxicity is a well-established risk factor for developing chronic OXAIPN at the end of chemotherapy.…”

Section: Pre-treatment Factorsmentioning

confidence: 99%

Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

Velasco

Alemany

Villagrán

et al. 2021

JPM

View full text Add to dashboard Cite

Oxaliplatin (OXA) is a platinum compound primarily used in the treatment of gastrointestinal cancer. OXA-induced peripheral neurotoxicity (OXAIPN) is the major non-hematological dose-limiting toxicity of OXA-based chemotherapy and includes acute transient neurotoxic effects that appear soon after OXA infusion, and chronic non-length dependent sensory neuronopathy symmetrically affecting both upper and lower limbs in a stocking-and-glove distribution. No effective strategy has been established to reverse or treat OXAIPN. Thus, it is necessary to early predict the occurrence of OXAIPN during treatment and possibly modify the OXA-based regimen in patients at high risk as an early diagnosis and intervention may slow down neuropathy progression. However, identifying which patients are more likely to develop OXAIPN is clinically challenging. Several objective and measurable early biomarkers for OXAIPN prediction have been described in recent years, becoming useful for informing clinical decisions about treatment. The purpose of this review is to critically review data on currently available or promising predictors of OXAIPN. Neurological monitoring, according to predictive factors for increased risk of OXAIPN, would allow clinicians to personalize treatment, by monitoring at-risk patients more closely and guide clinicians towards better counseling of patients about neurotoxicity effects of OXA.

show abstract

“…10,11 The drug choice was based on the type of primary tumor, the preexistent response to oxaliplatin for digestive cancers, and the presence of neuropathy, as detailed elsewhere. 6,12 The planned regimen included a standard of three procedures, but PIPAC treatment could be continued thereafter. When no clinical improvement was observed or early tumoral progression was identified, treatment was stopped prematurely after one or two ePIPACs.…”

Section: Study Design and Patient Selectionmentioning

confidence: 99%

Pressurized Intraperitoneal Aerosol Chemotherapy Enhanced by Electrostatic Precipitation (ePIPAC) for Patients with Peritoneal Metastases

et al. 2020

View full text Add to dashboard Cite

Background. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new mode of intraperitoneal chemotherapy administration that can potentially be improved by the addition of electrostatic precipitation (ePIPAC). This study aimed to describe the procedural details of ePIPAC and to analyze its safety for patients with nonresectable peritoneal metastasis as well as their tolerance and response to this treatment. Methods. This retrospective cohort study included consecutive patients treated with ePIPAC in three centers from April 2019 to April 2020. The toxicities of each patient were assessed using the Common Terminology Criteria for Adverse Events (CTCAE). Complications were documented according to the Clavien classification. Quality of life (QoL) was assessed using EORTC-QLQ-C30, and the peritoneal regression grading score (PRGS) was used to grade histologic responses. Further surrogates for responses were the Peritoneal Cancer Index (PCI), ascites, and symptoms. Results. Overall, 69 patients received 147 ePIPACs with oxaliplatin (n = 34) or cisplatin/doxorubicin (n = 35) mainly for colorectal (n = 25), ovarian (n = 14), and gastric (n = 13) primary cancers. Systemic chemotherapy was

show abstract

Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer

Cited by 5 publications

References 19 publications

Tolerability of Oxaliplatin-based Neoadjuvant Chemoradiotherapy in Elderly Locally Advanced Rectal Cancer Patients: A Case-control Study of a Real-life Experience

Tolerability of Oxaliplatin-based Neoadjuvant Chemoradiotherapy in Elderly Locally Advanced Rectal Cancer Patients: A Case-control Study of a Real-life Experience

Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity

Pressurized Intraperitoneal Aerosol Chemotherapy Enhanced by Electrostatic Precipitation (ePIPAC) for Patients with Peritoneal Metastases

Contact Info

Product

Resources

About